Elliott Management has built a large stake in GlaxoSmithKline

I have been buying GlaxoSmithKline stock ahead of the proposed split. An activist hedge fund taking a large stake in the company suggests they want something different. Here is what I am doing now.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Syringe and vial on blue background

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

According to the Financial Times, activist hedge fund Elliott Management has built a multibillion-pound stake in GlaxoSmithKline (LSE:GSK). The news broke today, and the GlaxoSmithKline share price is up 4.3% at the time of writing. Given that the broader FTSE 100 is up only 0.58%, and other large-cap pharma stock prices have budged only slightly, it’s reasonable to assume that Glaxo shareholders have taken the news well.

Activist hedge fund target

Elliott Management — which is headed up by billionaire investor Paul Singer — has a history of taking large stakes in companies that it feels are underperforming. It then uses its influence as a large shareholder to push the board to make changes that it thinks will increase shareholder value.

The GlaxoSmithKline share price has been underperforming its peers. It is down a little under 20% over three years. In contrast, the share prices of AstraZeneca and Pfizer, two notable peers, are up around 60% and 20%, respectively. Therefore, GlaxoSmithKline becoming the target of an activist hedge fund like Elliott Management is not a big surprise.

What is surprising is that major changes are already underway at GlaxoSmithKline. Investors have argued for years that the GlaxoSmithKline share price would do better if the company were to split. Investors calling for such a change are getting what they wanted.

What is Elliott Management after?

GlaxoSmithKline is due to split in 2022. The cash cow consumer healthcare business will go it alone with higher leverage and probably pay a stable dividend. The riskier biopharma business, dubbed ‘New Glaxo’, should emerge with lower debt and be able to invest heavily in a pipeline of new drugs.

GlaxoSmithKline told its shareholders about this plan over a year ago. Today’s announcement that Elliott Management has built a large stake suggests it is unhappy with the plan in part or in full. There is concern that the current CEO of GlaxoSmithKline, who previously has a successful tenure at personal care company L’Oréal, plans to head up the biopharma business after the split. The consumer healthcare division is thought to be better suited to the current CEO’s skill set.

It’s worth noting that GlaxoSmithKline has issued a dividend warning. After the split, the aggregate dividend is likely to be lower than the 80p paid for 2019. Perhaps this could be reason enough for Elliott to lobby against the company considering a lower payout.

It has also been suggested that GlaxoSmithKline’s sluggishness in developing a coronavirus vaccine, given its vaccine business is the jewel in its crown, is a motivating factor apart from the split. It’s worth noting that GlaxoSmithKline is collaborating on at least two Covid-19 vaccines at present.

GlaxoSmithKline share price

Without knowing what Elliott management wants, it’s impossible to speculate on the long-term effects of the activist hedge fund’s involvement on the GlaxoSmithKline share price. I am in favour of the split. Naturally, I would rather Elliott did not derail it. But, I can see the merits of arguing for the CEO to move to control the consumer healthcare business. As for vaccines, playing the long game might have been a shrewd move. Rolling vaccines out in record time have caused difficulties for others. It looks like Covid-19 will require multiple vaccines for quite some time.

Until I know more, I am continuing to buy GlaxoSmithKline shares ahead of the anticipated split.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

James J. McCombie owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »